4D Molecular Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue: | ||
| Collaboration and license revenue | $85,209 | $37 |
| Operating expenses: | ||
| Research and development (includes $1,322 and $1,005 for the years ended December 31, 2025 and 2024, respectively, attributable to related parties) | 195,696 | 141,299 |
| General and administrative | 49,060 | 46,579 |
| Total operating expenses | 244,756 | 187,878 |
| Loss from operations | (159,547) | (187,841) |
| Other income (expense): | ||
| Interest income | 19,475 | 27,050 |
| Other expense, net | (37) | (77) |
| Total other income, net | 19,438 | 26,973 |
| Net loss | $(140,109) | $(160,868) |
| Net loss per share, basic and diluted | $(2.42) | $(2.98) |
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 57,930,180 | 53,943,741 |
The accompanying notes are an integral part of these financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.